Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,724 JPY | -2.56% | +3.67% | +17.85% |
May. 15 | Correction: Terumo’s Profit Up 47% in Fiscal 2024 | MT |
May. 15 | Terumo’s Profit Up 47% in Fiscal 2023 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company is in a robust financial situation considering its net cash and margin position.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 37.56 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 4.49 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+17.85% | 26.02B | A- | ||
-5.43% | 181B | C+ | ||
+4.30% | 114B | C | ||
-3.09% | 68.29B | A | ||
+5.86% | 52.24B | B- | ||
+8.15% | 44.3B | B- | ||
+7.52% | 42.73B | B+ | ||
+25.54% | 32.52B | B | ||
+1.00% | 25.91B | A- | ||
-1.25% | 24.72B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4543 Stock
- Ratings Terumo Corporation